Gilead Sciences
S&P 500
Nasdaq 100
$143.72
-0.75%
Delayed · cached 15 min
Fair value analysis
GILD
Gilead Sciences
$143.72
Close used for this calculation
$112.99Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
49/100
Quality radar
Consensus fair value
$112.99
Above FV▼ -21.4% against the close used
Model range $6.78 – $141.20
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$6.78Fair value$112.99Bull$141.20
FairClose
52-week traded range
52W low $110.5652W high $155.80
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Gilead Sciences closed at $143.72, 27.2% above the consensus fair value of $112.99 drawn from 7 valuation models.
Financial DNA score 49/100 — Average. P/E of 21.2x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$141.20
-1.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
$135.60
-5.6%
EPS × 20x (sector P/E)
EPS=6.78, Sector P/E=20x
Peter Lynch (PEG)
$6.78
-95.3%
EPS × Growth% (PEG = 1 is fair)
EPS=6.78, g=1%
EV/EBITDA
$68.95
-52.0%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=10.39B
Dividend Discount (DDM)
$40.31
-72.0%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=3.16, r=10%, g=2%
Reverse DCF
$143.72
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 7.9% | Historical: -1%
Margin of Safety
$103.80
-27.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=138.4, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.